Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma.
Despite their efficacy in myeloma, corticosteroids have acute and chronic toxicities. Newer agents with significant anti-myeloma activity permit the development of steroid-free regimens. We designed a Phase II clinical trial to study the toxicity and efficacy of a steroid-free combination of bortezomib and thalidomide as a first-line treatment in patients with symptomatic myeloma. Patients received bortezomib 1·3 mg/m(2) on days 1, 4, 8 and 11 every 21 d and thalidomide 150 mg/d for a maximum of eight cycles. Amongst 27 evaluable patients, the overall response was 81·5% with 25·8% near complete response or greater. The response rate was comparable to most other two drug combinations for upfront therapy but lower than that obtained with the use of three drugs. The most common grade 3 toxicities were peripheral neuropathy (22%), pneumonia (15%), fatigue (7%) and anaemia (7%). Peripheral neuropathy completely resolved in 80% of the patients upon completion of therapy, but not in the remaining 20% of patients. No venous thromboembolic events were observed even in the absence of prophylactic anticoagulation. The median progression-free survival was 16·8 months (95% confidence interval 8·7-21·6 months). Median overall survival has not yet been reached at a median follow up of 39 months. The 3-year overall survival was 74%. This study demonstrates: (i) the efficacy of a steroid-free regimen; (ii) mostly reversible treatment-related peripheral neuropathy; and (iii) the absence of venous thrombotic events.
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 1650 Orleans St., Baltimore, MD 21231, USA.
Nilanjan
N
Ghosh
Xiaobu
X
Ye
Anna
A
Ferguson
Carol Ann
CA
Huff
Ivan
I
Borrello
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects; D000069286:Bortezomib; D004334:Drug Administration Schedule; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib
J Clin Oncol. 2002 Nov 1;20(21):4319-23
12409330
N Engl J Med. 2008 Aug 28;359(9):906-17
18753647
Cancer. 2010 Jul 1;116(13):3143-51
20564642
J Clin Oncol. 2002 Nov 15;20(22):4420-7
12431963
Blood. 2003 Jun 1;101(11):4569-75
12576322
J Clin Oncol. 2008 May 1;26(13):2171-7
18362366
Br J Haematol. 2005 Jun;129(6):776-83
15953004
Blood. 2009 Apr 9;113(15):3435-42
18955563
Haematologica. 2006 Nov;91(11):1498-505
17043025
J Peripher Nerv Syst. 2008 Dec;13(4):275-82
19192067
Hematology. 2007 Jun;12(3):235-9
17558699
J Clin Oncol. 2006 Jan 20;24(3):431-6
16365178
Cancer Res. 1999 Jun 1;59(11):2615-22
10363983
J Clin Oncol. 2007 Oct 1;25(28):4452-8
17785704
Lancet Oncol. 2010 Jan;11(1):29-37
19853510
Leukemia. 2006 Sep;20(9):1467-73
16855634
Blood. 2002 Jun 15;99(12):4525-30
12036884
Haematologica. 2004 Jul;89(7):826-31
15257934